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Abstract: Lung cancer is the leading cause of cancer death in the United States. The majority of 
patients present with advanced stage disease, and treatment with standard cytotoxic chemotherapy 
agents have been shown to provide a modest improvement in survival, reduce disease-related 
symptoms, and improve quality of life. However, with standard chemotherapy treatments the 
prognosis is poor with the majority of patients dying in less than a year from diagnosis. Treatment 
with standard chemotherapy agents has reached a therapeutic plateau, and recent investigations 
have focused on therapies that target a speciﬁ  c pathway within the malignant cell or related to 
angiogenesis. The most promising of the targeted therapies are agents that target the process 
of angiogenesis. Bevacizuamab is a monoclonal antibody that binds to circulating vascular 
endothelial growth factor (VEGF)-A, and prevents binding of VEGF to vascular endothelial 
growth factor receptors, thus inhibiting activation of the VEGF pathway and angiogenesis. A 
recent phase III trial of ﬁ  rst-line treatment of advanced non-small cell lung cancer revealed a 
statistically signiﬁ  cant improvement in response, progression-free survival, and overall survival 
with the combination of bevacizumab and standard chemotherapy in comparison to standard 
chemotherapy alone. Bevacizumab is the only targeted therapy that has been shown to improve 
survival when combined with standard chemotherapy in the ﬁ  rst-line setting.
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Introduction
In the United States, lung cancer is the leading cause of cancer deaths among both 
men and women, and it is estimated that in 2007 that more people will die of lung 
cancer than breast, colon, and prostate cancer combined (Jemal et al 2007). Approxi-
mately 85% will have the non-small cell histology, and two-thirds will present with 
advanced stage disease (Bulzebruck et al 1992; Govindan et al 2006). Advanced stage 
is generally deﬁ  ned as malignant involvement of the supraclavicular lymph nodes, 
malignant pleural or pericardial effusions, or metastases to a different lobe of the lung 
or another organ. The most frequent sites of metastases are the liver, bone, brain, or 
adrenal gland. In addition to the patients who present with advanced stage a high 
percentage of patients who present with early stage disease and undergo a potentially 
curative surgical resection will subsequently relapse with metastatic disease (Pisters 
and Le Chevalier 2005). The primary therapy in advanced stage and relapsed disease 
is chemotherapy. The current standard therapy for patients with a preserved functional 
status is double agent chemotherapy (Pﬁ  ster et al 2004). The median survival with 
chemotherapy is 8–10 months, and the 1- and 2-year survival rates are 20%–30% 
and 10%–20%, respectively (Schiller et al 2002; Treat et al 2005). Most patients will 
receive 4–6 cycles of double agent chemotherapy. Extending the duration of double 
agent therapy has not been shown to improve survival, and results in a higher rate of 
treatment-related toxicity (Socinski et al 2002; Smith et al 2001). Additional treatment 
with single agent “maintenance” chemotherapy initiated after completion of double Biologics: Targets & Therapy 2007:1(3) 186
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agent platinum therapy has not been shown to extend survival 
(Westeel et al 2005).
After initial treatment with chemotherapy all patients 
inevitably experience disease progression, generally in a 
median of 3–5 months after initiating chemotherapy. After 
completion of the initial chemotherapy treatment patients 
are observed and upon evidence of disease progression 
patients with a preserved functional status may be treated 
with additional therapy, often referred to as second-line 
therapy. There are currently three agents approved by the 
Food and Drug Administration (FDA) for second-line treat-
ment advanced NSCLC: two cytotoxic agents, docetaxel 
(Taxotere®; Aventis Pharmaceuticals Inc., Bridgewater, NJ, 
USA) and pemetrexed (Alimta®; Eli Lilly and Company; 
Indianapolis, IN, USA), and erlotinib (Traceva®; Genentech, 
Inc., South San Francisco, CA and OSI Pharmaceuticals, 
Inc., Melville, NY, USA), an epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor (TKI) (Fossella 
et al 2000; Shepherd et al 2000, 2005; Hanna et al 2004). It 
appears from recent trials of ﬁ  rst-line therapy that 40%–50% 
of patients will subsequently receive second-line therapy 
(Socinski et al 2002; Sandler et al 2006a). Patients with non-
squamous histology, female gender, and a good functional 
status appear to be more likely to receive second-line therapy 
(Hensing et al 2005). The median survival and 1-year sur-
vival rate on second-line trials has been 6–8 months, and 
30%, respectively (Fossella et al 2000; Hanna et al 2004; 
Shepherd et al 2000, 2005).
Given the modest survival of patients with advanced 
NSCLC, there has been signiﬁ  cant interest in improv-
ing on standard therapies. Numerous clinical trials have 
compared treatment with two cytotoxic chemotherapy 
agents to treatment with three agents, and a recent meta-
analysis revealed that the addition of third agent did not 
improve survival, but did result in increased toxicity 
(Delbaldo et al 2004). This has led to the belief that we 
have reached a “therapeutic plateau” in the treatment of 
advanced NSCLC with standard cytotoxic agents. There is 
signiﬁ  cant interest in integrating the “targeted” therapies 
into the treatment of NSCLC. The hope is that advances in 
the understanding of the molecular biology of cancer cells 
will lead to therapeutic agents that speciﬁ  cally target the 
malignant processes within the cancerous cells, and have 
limited impact on the normal cellular processes. Thus, 
the newer targeted therapies may have increased efﬁ  cacy 
as well as a lower rate of toxicity. Erlotinib and geﬁ  tinib 
(Iressa®; AstraZenca Pharmaceuticals, Wilmington, DE, 
USA), which speciﬁ  cally target the intra-cellular tyrosine 
kinase of the EGFR are examples of a targeted therapy 
in NSCLC.
There was initially tremendous enthusiasm that targeted 
therapy would improve ﬁ  rst-line therapy in NSCLC; how-
ever, the initial enthusiasm has been tempered by the results 
of recent of phase III trials. Two target therapies, erlotinib 
and geﬁ  tinib revealed promising results as single agent activ-
ity in phase II trials (Fukuoka et al 2003; Kris et al 2003; 
Perez-Soler et al 2005). These led to the development of 
four phase III trials that compared standard chemotherapy 
to EGFR TKI therapy in combination with chemotherapy. 
Unfortunately these trials revealed that the addition of EGFR-
TKI therapy did not improve response or survival (Giaccone 
et al 2004; Gatzemeier et al 2007; Herbst et al 2004, 2005c). 
Two phase III trials SPIRIT I and SPIRIT II, investigated 
the addition of bexarotene, a synthetic retinoid analog that 
preferentially binds to the rexinoid X receptor (RXR), to 
standard chemotherapy based on promising phase II data 
(Khuri et al 2001). Neither trial revealed an improvement in 
progression free survival or overall survival (Blumesnschein 
et al 2005; Jassam et al 2005). Phase III trials with matrix 
metalloproteinase inhibitors (MMPI) in combination with 
chemotherapy failed to revealed a survival beneﬁ  t over stan-
dard chemotherapy as well (Smylie et al 2001; Bissett et al 
2005). These trials have demonstrated that the integration of 
targeted therapy into ﬁ  rst-line therapy for advanced NSCLC 
will be more difﬁ  cult than initially anticipated.
Angiogenesis as a target
The development of new blood vessels, referred to as angio-
genesis, is essential for solid tumor growth beyond 2–3 mm3 
(Folkman 1992). The physiologic role of angiogenesis 
in the healthy adults is limited to wound healing and the 
menstrual cycle (Ferrara et al 2003). A complex interaction 
of numerous stimulatory and inhibitory factors carefully 
regulates the process of angiogenesis. Tumors may remain 
dormant in an avascular phase; however, when the stimu-
lating factors exceed the inhibitory factors an “angiogenic 
switch” occurs, and tumors initiate angiogenesis (Bergers 
and Benjamin 2003). Once the angiogenic switch occurs, 
a process of endothelial cell migration and proliferation, 
capillary tube formation, and the release of proangiogenic 
stimulating factors is initiated (Herbst et al 2005b). Vascular 
endothelial growth factor (VEGF)-A acts as the primary 
mediator of these processes (Bergers and Benjamin 2003). 
Other growth factors involved in this process include plate-
let-derived growth factor (PDGF), basic ﬁ  broblast growth 
factor, and transforming growth factor β (Ellis and Fidler Biologics: Targets & Therapy 2007:1(3) 187
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1996). Solid tumors may also develop the ability to secrete 
proangiogenic factors to support further angiogenesis and 
metastases (Folkman 1990; Herbst et al 2005b). Some tumor 
cells may express VEGF receptors, thus VEGF secretion 
may act as an autocrine as well as paracrine factor (Masood 
et al 2001). The development of these new blood vessels, 
often referred to as neovascularization, allows further growth 
of the primary tumor and the development of metastases 
by providing a pathway for tumor cells to circulate in the 
systemic circulation and establish additional metastases 
(Sandler et al 2004).
VEGF binds to two different tyrosine kinase receptors: 
VEGF receptor (VEGFR)-1 (also known as Flt-1), and 
VEGFR-2 (also known as KDR). VEGFR-1 and VEGFR-
2 are predominantly located on endothelial cells, and 
receptor expression on normal tissues is low, and only up 
regulated during neovascularization (Shibuya et al 1990; 
Terman et al 1992; Brown et al 1993). VEGF binding 
to VEGFR-1 mediates angiogenesis, while binding to 
VEGFR-2 mediates angiogenesis and lymphangiogenesis 
(Ferrara et al 2003). There is third receptor, VEGR-3, 
which is predominantly involved in the regulation of 
lymphangiogenesis (Gerber and Ferrara 2005). VEGF 
has been associated the development of hyperpermeable, 
immature vasculature, which is typical of malignancy 
related angiogenesis (Dvorak et al 1995; Bates et al 2001; 
Ferrara et al 2003).
The role of angiogenesis in the progression of lung can-
cer is well established with multiple studies revealing that 
a high microvessel density is associated with the develop-
ment of metastases and poor survival (Fontanini et al 1995; 
Lucchi et al 1997; D’Amico et al 1999; Yano et al 2000). 
High vascular density has also been associated with tumor 
progression (Ushijima et al 2001). VEGF is also known as 
vascular permeability factor, and may be associated with the 
development of brain edema, malignant pleural effusions, and 
ascites (Senger et al 1983; Yanagawa et al 1999; Ferrara et al 
2003). The extensive preclinical data suggested that angio-
genesis was critical to the pathogenesis and development of 
metastases in NSCLC.
There are currently multiple anti-angiogenesis agents 
being investigated in clinical trials for non-small cell lung 
cancer; however, the only one currently approved for the 
treatment of NSCLC by the Food and Drug Administration 
(FDA) is bevacizumab (Avastin®; Genentech, Inc South 
San Francisco, CA, USA). Bevacizumab is a recombinant 
humanized monoclonal antibody that binds to circulating 
VEGF preventing VEGF from binding to its receptors. 
Bevacizumab as a single agent has limited clinical activity, 
and in a phase I clinical trial in patients with solid tumors no 
responses were seen in the 23 patients evaluable for response 
(Gordon et al 2001). Twelve patients did have stable dis-
ease over the duration of the study. Thus, as single agent 
bevacizumab appears to be cytostatic; however, treatment 
with bevacizumab is synergistic with chemotherapy. In a 
pivotal phase III trial in metastatic colorectal cancer, patients 
treated with chemotherapy and bevacizumab had a superior 
survival to patients treated with the same chemotherapy 
(Hurwitz et al 2004). The synergistic effects of bevacizumab 
have been attributed to a reduction of vascular permeability 
and normalization of the tumor vasculature resulting in 
decreased interstitial pressure within the tumor. (Jain 2001) 
The reduction in the interstitial pressure is believed to result 
in improved delivery of cytotoxic therapy to the malignant 
cells (Jain 2001). Preclinical data indicates that treatment 
with VEGF-blocking therapy does increase the intratumoral 
uptake of chemotherapy (Wildiers et al 2003). Other pos-
sible mechanisms for the synergy with chemotherapy by 
bevacizumab include inhibiting re-population of the malig-
nant cells in the interval between chemotherapy cycles, and 
augmenting the anti-angiogeneis effects of chemotherapy 
(Kerbel 2006).
Bevacizumab in the treatment of 
NSCLC
A phase I trial in patients with solid tumors revealed that 
bevacizumab could be safely combined with standard doses 
of carboplatin (Paraplatin®: Bristol-Meyers Squibb; Princ-
eton, NJ, USA) and paclitaxel (Taxol®; Bristol-Meyers 
Squibb; Princeton, NJ, USA) (Margolin et al 2001). This 
led to the development of a randomized phase II trial in 
patients with advanced NSCLC. Ninety-nine patients were 
enrolled in this trial, and all patients received carboplatin 
area under the curve (AUC) = 6 using the Calvert equation, 
and paclitaxel 200 mg/m2 every 3 weeks, and patients on 
the two investigational arms received bevacizumab 7.5 mg/
kg (n = 32) or 15 mg/kg (n = 35) every 3 weeks until dis-
ease progression (Calvert et al 1989; Johnson et al 2004). 
Patients on all three arms received a median of 6 cycles of 
carboplatin and paclitaxel and patients on the low-dose and 
high-dose bevacizumab arms received a median of 8 and 
10 doses of bevacizumab, respectively. Treatment with the 
high-dose bevacizumab resulted in statistically signiﬁ  cant 
longer time to tumor progression in comparison to the con-
trol arm (7.4 months vs 4.2 months; p = 0.023). There was 
no signiﬁ  cant difference in the time to tumor progression Biologics: Targets & Therapy 2007:1(3) 188
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between the carboplatin and paclitaxel arm and the low-dose 
bevacizumab arm (Table 1). Patients who received carbo-
platin and paclitaxel could receive single agent therapy with 
bevacizumab upon disease progression. Nineteen patients 
received second-line therapy with single bevacizumab, and 
ﬁ  ve patients experienced stable disease. The median survival 
and one-year survival rate from the time of initiating beva-
cizumab therapy in this subgroup of patients was 10 months 
and 47%, respectively.
This trial revealed several notable bevacizumab related 
adverse events including hypertension, proteinuria, and 
episodes of hemorrhage. The episodes of hemorrhage 
consisted of two distinct clinical entities: minor muco-
cutaneous hemorrhage, predominantly epistaxis, and life 
threatening hemorrhage. Six patients experienced life 
threatening hemoptysis or hemorrhage, and four events 
were fatal. Squamous histology appears to be associated 
with the development of this complication since four of the 
13 patients with squamous histology (31%) experienced 
severe hemorrhage versus two of the 54 (4%) of patients 
with non-squamous histology. Five of the six had cavitation 
at baseline or tumor necrosis during the therapy. Pulmonary 
hemorrhage may be associated with central location; 
however, central location may be a surrogate marker for 
histology since squamous cell tumors tend to be centrally 
located. Five of the six episodes occurred on the low-dose 
treatment arm, and events occurred early ( 60 days) as 
well as late ( 180 days); thus the events did not appear to 
be dose- or time-dependent.
If a subset analysis is performed in patients with the 
non-squamous histology (n = 79) it appears that the addi-
tion of bevacizumab to standard chemotherapy improves the 
response rate, time to tumor progression, and overall survival 
(Table 1). Based on the promising results of this phase II trial, 
the Eastern Cooperative Oncology Group (ECOG) initiated 
a phase II/III trail, ECOG 4599, comparing the standard 
therapy of carboplatin and paclitaxel to the combination of 
carboplatin, paclitaxel, and bevacizumab (15 mg/kg) every 
3 weeks in patients with advanced stage non-squamous 
histology (Sandler et al 2006a). Exclusion criteria were: 
hemoptysis (deﬁ  ned as  1/2 a teaspoon of bright red blood); 
central nervous system metastases; clinically signiﬁ  cant 
cardiovascular disease; medically uncontrolled hyperten-
sion; documented hemorrhagic diathesis or coagulopathy; 
anticoagulation therapy; regular use of aspirin ( 325 mg 
daily), non-steriodal anti-inﬂ  ammatory agents, or other 
agents known to inhibit platelet function. Patients could not 
have received radiation therapy within 21 days of enrollment 
or major surgery within 28 days of enrollment. Patients were 
required to have computed tomography (CT) scan or mag-
netic resonance imaging (MRI) of the brain within four weeks 
of enrollment to evaluate for brain metastases. Importantly, 
patients with centrally located tumors were not excluded. Of 
the 878 patients enrolled on the trial, 444 received carboplatin 
and paclitaxel and 434 received carboplatin, paclitaxel, and 
bevacizumab.
There was a statistically signiﬁ  cant improvement in the 
response rate, progression-free survival, and overall survival 
in the bevacizumab containing arm (Table 2). This trial 
led the FDA to approve bevacizumab for the treatment of 
patients with advanced stage NSCLC with non-squamous 
histology in combination with carboplatin and paclitaxel. 
On a subgroup analysis no survival beneﬁ  t was seen among 
women with treatment with bevacizumab despite a statisti-
cally signiﬁ  cant improvement in response and progression 
free survival (Brahmer et al 2006). The test for a treatment 
gender interaction in a proportional hazards model for sur-
vival was statistically signiﬁ  cant (p = 0.04). It is important 
to note that this trial was not statistically powered to evalu-
ate the efﬁ  cacy of bevacizumab in subgroups. The reasons 
Table 1 Efﬁ  cacy results of a three-arm randomized phase II trial with carboplatin and paclitaxel with and without bevacizumab Johnson 
et al (2004).













n = 32 n = 32 n = 34 n = 25 n = 22 n = 32
Response (%)a 18.8 28.1 31.5 Response (%) 20 31.8 50
Median TTP (months) 4.2 4.3 7.4 Median TTP (months) 4.0 6.3 7.1
Survival (months) 14.9 11.6 17.7 Survival (months) 12.2 14.0 17.8
aResponse as assessed by the investigator
Abbreviations: C/P, carboplatin and paclitaxel; TTP, time to progression.Biologics: Targets & Therapy 2007:1(3) 189
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for the lack of a survival beneﬁ  t in women are unclear, and 
potential explanations include an imbalance in unrecognized 
prognostic factors, statistical chances, or a true lack of 
beneﬁ  t among women. There were no survival differences in 
survival related to gender on the previous trial of metastatic 
colorectal cancer (Hurwitz et al 2004). Until the potential 
relationship between gender and overall survival can be 
clariﬁ  ed, female patients who meet the eligibility criteria 
for the trial should be considered candidates for treatment 
with bevacizumab.
The bevacizumab-containing treatment arm did have a 
signiﬁ  cantly higher rate of toxicity than the carboplatin and 
paclitaxel treatment arm. The bevacizumab containing arm 
had a higher rate National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) grade 
4 neutropenia (25.5% vs 16.8%, respectively; p = 0.002), 
thrombocytopenia (1.6% vs 0.2%, respectively; p = 0.04), and 
febrile neutropenia (5.2% vs 2.0%, respectively; p = 0.02). 
There was a higher rate of non-hematologic toxicity as well 
including grade 3–5 hypertension (7% vs 0.7%, respec-
tively; p   0.001), hemorrhage (4.4% vs 0.7%, respectively; 
p   0.001), and grade 3 proteinuria (3.1% vs 0%, respec-
tively; p   0.001). There were seven hemorrhage-related 
deaths on the bevacizumab arm (pulmonary hemorrhage 
(n = 5), and gastrointestinal bleeding (n = 2). The other 
causes of death on the bevacizumab arm were: complications 
of febrile neutropenia (n = 5), cerebrovascular event (n = 2) 
and probable pulmonary embolism (n = 1). There were 15 
treatment-related deaths on the bevacizumab arm versus two 
on the standard treatment arm (p = 0.001).
An exploratory retrospective analysis of the episodes of 
pulmonary hemorrhage occurring  150 days from initiation 
treatment was performed. (Sandler et al 2006b) This analy-
sis used a case-control method in an attempt to identify 
radiographic and clinical risk factors for the development of 
severe pulmonary hemorrhage. Hemoptysis at baseline, and 
tumor cavitation were identiﬁ  ed as probable risk factors for 
pulmonary hemorrhage. Central location was not identiﬁ  ed 
as a risk factor. Given the small number of cases involved in 
this analysis a larger analysis which included patients from 
ongoing clinical trials may provide additional information 
about risk factors for pulmonary hemorrhage, and the relative 
risk associated with each risk factor.
In addition to these two trials, a third trial, known as 
AVAil (BO17704) has completed enrollment, and the pre-
liminary results were presented at the American Society 
of Clinical Oncology meeting in June 2007 (Manegold 
et al 2007). This was a three arm trial designed to compare 
the efﬁ  cacy of chemotherapy and two different doses of 
bevacizumab versus chemotherapy alone, and was not 
designed for a comparison of the efﬁ  cacy of two different 
doses of bevacizumab. To be eligible for this trial patients 
were required to have non-squamous histology, a preserved 
functional status, and chemotherapy-naïve stage IIIB/IV or 
recurrent NSCLC. The exclusion criteria were: grade  2 
hemoptysis; radiological evidence of tumor invasion of major 
blood vessels; brain metastases or spinal cord compression; 
uncontrolled hypertension; history of thrombotic or hemor-
rhagic disorders; and therapeutic anticoagulation within 
10 days of the ﬁ  rst treatment. The initial primary end-point 
was an improvement in overall survival with the combina-
tion of chemotherapy and bevacizumab versus chemotherapy 
alone; however, after enrollment on the trial had begun the 
trial was amended and the primary end-point was changed 
to progression-free survival.
One thousand and forty-three patients were enrolled on 
the trial, and patients were randomized to three arms: cis-
platin (80 mg/m2) on day 1 and gemcitabine 1250 mg/m2 on 
days 1, 8 and placebo every 3 weeks (n = 347) or the same 
chemotherapy with either 7.5 mg/kg (n = 345) or 15 mg/kg 
(n = 351) every 3 weeks. Bevacizumab was continued until 
disease progression and no crossover to bevacizumab was 
allowed. Patients on the chemotherapy and bevacizumab 
arms experienced a statistically signiﬁ  cant improvement in 
the progression-free survival in comparison to the pooled 
placebo; cisplatin, gemcitabine, and bevacizumab 7.5 mg/kg 
arm versus pooled placebo (hazard ratio [HR] = 0.75; 95% 
conﬁ  dence Interval [CI] 0.62–0.91, p = 0.0026) and cisplatin, 
gemcitabine and bevacizumab 15 mg/kg versus pooled pla-
cebo (HR = 0.82; 95% CI 0.68–0.98, p = 0.0301). The median 
Table 2 ECOG 4599 trial efﬁ  cacy results (Sandler et al 2006a).
Parameter C/P C/P+B Hazard ratio p-value
Response (%) 15% 35% Not applicable <0.001
PFS (median) 4.5 months 6.2 months 0.66 (95% CI, 0.57–0.77 <0.001
Overall survival 10.3 12.3 months 0.79 (95% CI, 0.67–0.91) 0.003
Abbreviations: C/P, carboplatin and paclitaxel; C/P+B, carboplatin, paclitaxel, and bevacizumab; PFS, progression free survival; CI, conﬁ  dence interval.Biologics: Targets & Therapy 2007:1(3) 190
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progression-free survival time for cisplatin and gemcitabine; 
cisplatin, gemcitabine and bevacizumab 7.5 mg/kg; and 
cisplatin, gemcitabine, and bevacizumab 15 mg/kg were 6.1 
months, 6.7 months, and 6.5 months, respectively. At the time 
of this analysis the protocol-speciﬁ  ed number of events for 
fully powered survival analysis has not been reached. The 
rate of grade  3 neutropenia, febrile neutropenia hemor-
rhage, and pulmonary hemorrhage were similar in all treat-
ment arms. The rate of grade  3 pulmonary hemorrhage 
and febrile neutropenia for the cisplatin and gemcitabine, 
cisplatin, gemcitabine, bevacizumab 7.5 mg/kg and 15 mg/kg 
arms was 0.3%, 1.2%, and 0.9%, respectively and 1%, 2%, 
and 2%, respectively. The ﬁ  nal results of this trial should 
provide valuable toxicity data; however, the trial design may 
limit conclusions that can be made in regards to the survival 
beneﬁ  t of bevacizumab and the relatively efﬁ  cacy of the two 
doses of bevacizumab.
Second-line trials
Two phase II trials have investigated the role of bevaci-
zumab in patients with non-squamous histology who have 
progressed after initial chemotherapy treatment. Neither of 
these trials included patients who had received prior bevaci-
zumab therapy, and the eligibility criteria were similar to the 
criteria used in ECOG 4599. A phase I/II trial investigated 
the toxicity and efﬁ  cacy of bevacizumab in combination with 
erlotinib, an oral EGFR-TKI in patients who had received 
at least one prior line of chemotherapy for NSCLC (Herbst 
et al 2005a). Forty patients were enrolled on this trial, and 
22 (55%) had received   two prior lines of chemotherapy. 
No dose-limiting toxicities were observed in the phase I 
portion, and the phase II dose was established as erlotinib 
150 mg daily and bevacizumab 15 mg/kg every 3 weeks. 
The most common toxicities observed were rash, diarrhea, 
hematuria, and proteinuria. No signiﬁ  cant myelosuppression 
was observed.
The combination demonstrated signiﬁ  cant activity with 
eight patients (20%) experiencing partial response, and 26 
patients (65%) experiencing stable disease as their best 
response. The median survival for the 34 patients on the phase 
II dose was 12.6 months, and the progression-free survival 
was 6.2 months. Nine patients were never-smokers (22.5%) 
which has been associated with a higher response rate to 
erlotinib (Pao et al 2004). EGFR mutations have also been 
associated with increased response to EGFR-TKI therapy, 
and 9 patients had sufﬁ  cient parafﬁ  n-embedded tissue for 
EGFR mutational analysis (Lynch et al 2004; Paez et al 
2004; Pao et al 2004). These 9 patients included 3 patients 
with partial response, 3 patients with stable disease, and 
3 patients with progressive disease.
A 3-arm randomized phase II trial investigated the 
safety and activity of bevacizumab in the second-line set-
ting (Fehrenbacher et al 2006). Patients with central lesions, 
cavitation, or lesion proximal to major blood vessels were 
excluded. One hundred and twenty patients were randomized 
to one of the three treatment arms; second-line chemotherapy 
alone (pemetrexed or docetaxel) (n = 41), second-line che-
motherapy (pemetrexed or docetaxel) in combination with 
bevacizumab (n = 40), and erlotinib in combination with 
bevacizumab (n = 39). There was a trend toward improved 
progression free survival with the addition of bevacizumab 
to chemotherapy (HR = 0.66; 95% CI 0.38–1.16) and 
bevacizumab and erlotinib (HR = 0.72; 95% CI 0.42–1.23) 
in comparison to chemotherapy alone. The difference in 
progression-free survival and overall survival did not reach 
statistical signiﬁ  cance, and due to the trial design it cannot 
be deﬁ  nitively determined if treatment with the bevacizumab 
results in superior survival to standard therapy in the second-
line setting. The preliminary safety data indicates that the rate 
of grade 3–5 hemorrhage was 5.1%, and the overall rate of 
neutropenia was similar between the two chemotherapy treat-
ment arms. This trial provides valuable safety data about the 
use of bevacizumab in the second-line setting, and the trend 
toward improvement on progression free survival is intrigu-
ing but is insufﬁ  cient to recommend the use of bevacizumab 
in the second-line setting.
Special populations
The eligibility criteria for ECOG 4599 trial excluded a sig-
niﬁ  cant percentage of the advanced NSCLC population. On 
recent United States cooperative group trials or multi-center 
trials the prevalence of brain metastases was 8%–17% (Treat 
et al 2005; Wakelee et al 2006a). Previously, imaging of the 
brain was only recommended if there was a clinical suspicion 
of brain metastases (Pﬁ  ster et al 2004). However, now that 
the presence or absence if brain metastases may impact the 
therapeutic decisions the rate of brain imaging may increase 
which in turn will lead to more patients who have brain 
metastases that are detected. Magnetic resonance imaging 
(MRI) is more sensitive than CT scans, and an increase in 
the use of MRI may lead to an increase in the prevalence of 
brain metastases as well (Schellinger et al 1999). Patients 
with brain metastases have been excluded from bevacizumab 
trials based on a single episode of central nervous hemorrhage 
in a patient with a brain metastases due to hepatocellular 
carcinoma on a phase I trial (Gordon et al 2001). Given the Biologics: Targets & Therapy 2007:1(3) 191
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prevalence of brain metastases there is signiﬁ  cant interest 
in investigating the safety of bevacizumab in patients with 
brain metastases from NSCLC. A phase II trial (known as the 
PASSPORT trial) of bevacizumab in combination with ﬁ  rst 
or second-line chemotherapy is currently enrolling patients. 
The primary end-point is the incidence of NCI grade  2 
central nervous system hemorrhage, and secondary objectives 
will be overall survival and toxicity. The interval between 
completion of the radiation therapy for brain metastases and 
the initiation of bevacizumab containing therapy is required 
to be a minimum of four weeks, and the choice of systemic 
therapy is at the discretion of the treating physicians.
There is also signiﬁ  cant interest in determining if bevaci-
zumab therapy can be used safely in patients with squamous 
histology. The prevalence of squamous histology on recent 
ECOG trials is estimated to be approximately 20%, and the 
decision to exclude patients with squamous histology was 
based on the toxicity seen with 13 patients on the phase II 
trial (Johnson et al 2004; Wakelee et al 2006a). The current 
hypothesis for the pathogenesis of pulmonary hemorrhage 
is that bevacizumab therapy induces central necrosis or 
enlargement of a pre-existing cavitation. The combination of 
a rapid response and the immature blood vessels of the tumor 
may result in hemorrhage into the tumor cavity (Johnson 
et al 2004). Treatment with thoracic radiation therapy, a 
standard therapy for hemoptysis, may reduce the risk of 
patients with squamous histology developing pulmonary 
hemorrhage. A trial to investigate this treatment approach 
is currently in development. Another phase II trial (known 
as the BRIDGE trial) will treat patients with squamous 
histology with two cycles of carboplatin and paclitaxel, and 
then initiate bevacizumab in combination with carboplatin 
and paclitaxel for the remaining cycles of therapy. Patients 
will receive bevacizumab until disease progression. The 
hypothesis is that the risk of pulmonary hemorrhage will 
be decreased with the delayed initiation of bevacizumab. 
The primary end-point will be the incidence of grade  3 
pulmonary hemorrhage.
Duration of bevacizumab therapy
The optimal duration of bevacizumab therapy is another 
important clinical question. Patients on ECOG 4599 
continued treatment until disease progression. Of the 
407 patients who initiated treatment with carboplatin, 
paclitaxel, and bevacizumab, 215 (53%) continued treat-
ment with bevacizumab monotherapy, and of these 107 
(50%) received greater than ﬁ  ve cycles of bevacizumab 
monotherapy. Treatment with single agent bevacizumab 
may cause regression of vasculature and inhibit the growth 
of new blood vessels which could have cytostatic effects 
on tumor growth and extend the progression free survival. 
Clinical data about the single-agent activity of bevacizumab 
are limited. On the phase II trial 19 patients who received 
ﬁ  rst-line therapy with carboplatin and paclitaxel did sub-
sequently receive single agent bevacizumab upon disease 
progression (Johnson et al 2004). Five patients did experi-
ence stable disease. This is a very small cohort to base any 
decisions about the efﬁ  cacy of single agent bevacizumab in 
NSCLC. The concerns about continuing the bevacizumab 
are the development of resistance, the longer duration of 
exposure to treatment related complications, and the poten-
tial development of cumulative toxicities. It is also possible 
that the majority of the beneﬁ  t the bevacizumab therapy may 
be obtained in a deﬁ  ned duration, and continuous therapy is 
not necessary. Until data are available the standard practice 
is to continue the bevacizumab until disease progression as 
done in the ECOG 4599 trial.
Future directions
Given the improvement in survival seen with advanced 
disease there is signiﬁ  cant interest in incorporating beva-
cizumab in the potentially curative treatments of adjuvant 
therapy for patients with resectable disease and chemo-
radiotherapy for patients with locally advanced disease. 
Recent trials have revealed a survival beneﬁ  t to treatment 
with adjuvant cisplatin-based chemotherapy after complete 
resection (Arriagada et al 2004; Douillard et al 2005; Winton 
et al 2005). ECOG 1505 trial will compare cisplatin-based 
adjuvant therapy versus cisplatin-based therapy in combi-
nation with bevacizumab in patients with resected stage IB 
(tumors  4 cm) stage II, and stage III disease (Wakelee 
et al 2006b). Physicians will be able to select among three 
cisplatin-based chemotherapy combinations; however, the 
selection of the chemotherapy treatment will occur prior 
to randomization. Patients randomized to bevacizumab 
therapy will receive bevacizumab (15 mg/kg every 3 weeks) 
with the ﬁ  rst dose of chemotherapy, and for a total dura-
tion of one year. A phase II trial (known as the BEACON 
trial) is investigating neoadjuvant treatment (pre-operative 
chemotherapy) with bevacizumab in combination with cis-
platin and docetaxel in patients with resectable stage IB to 
IIIA NSCLC (Giaccone 2007). This trial will provide valu-
able data about the response rate of bevacizumab containing 
therapy in earlier stage disease.
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chemoradiotherapy is being coordinated by the University 
of North Carolina. Patients with squamous histology will be 
eligible, but patients with squamous histology that invade 
or abut major blood vessels will be excluded. The other 
inclusion or exclusion criteria were similar to ECOG 4599. 
Patients will receive carboplatin, paclitaxel, and bevacizumab 
for two cycles, and then will receive weekly carboplatin, 
paclitaxel, and bi-weekly bevacizumab (10 mg/kg) with con-
current thoracic radiotherapy to 74 Gy. If the initial cohorts 
tolerable toxicity proﬁ  le, intermittent erlotinib with thoracic 
radiology will be integrated in the treatment. The schedule 
of erlotinib is Tuesday through Friday, and the initial cohort 
will receive 50 mg daily. The ﬁ  nal planned cohort will receive 
erlotinib 150 mg daily. After completion of the thoracic 
radiation therapy patients will receive erlotinib 150 mg daily 
with bevacizumab 15 mg/kg every 3 weeks for 6 cycles. The 
erlotinib will be discontinued with the bevacizumab.
The Southwest Oncology Group (SWOG) is performing 
a phase I/II trial of bevacizumab, cisplatin and etoposide 
in combination with thoracic radiation for patients with 
unresectable stage IIIA/B disease (www.swog.org accessed 
3/25/2007). Two different schedules of bevacizumab during 
thoracic radiation therapy will be investigated on this trial. 
Patients with squamous histology will be excluded if tumor 
cavitation is present or the tumor is located within 10 mm 
of a major blood vessel. The other eligibility criteria are 
similar to ECOG 4599. After completion of the concurrent 
chemoradiotherapy part of the trial the patients will receive 
consolidation therapy with docetaxel and bevacizumab with 
growth colony stimulating factor (G-CSF) support during the 
consolidation therapy. The primary end-point will be the rate 
of grade 4 or 5 hemorrhage, and the secondary end-points 
will progression free survival and overall survival.
There is signiﬁ  cant interest in determining which patients 
are most likely to beneﬁ  t from bevacizumab-based therapy 
and identifying molecular markers that are predictive of 
beneﬁ  t of anti-angiogenesis therapy. An investigation of 
pretreatment biomarkers on ECOG 4599 revealed that VEGF 
levels did correlate with overall survival, and baseline intercel-
lular adhesion molecule (ICAM) levels were prognostic for 
survival and response to chemotherapy (Dowlati et al 2006). 
A retrospective analyses of 813 patients with metastatic 
colorectal cancer treated on the trial by Hurwitz et al inves-
tigated if VEGF, thrombospondin-2, and microvessel density 
were prognostic factors and/or predictors of beneﬁ  t from 
bevacizumab (Jubb et al 2006). Neither of the biomarkers or 
the microvessel density was signiﬁ  cant prognostic or predic-
tive factors. Future bevacizumab trials will likely incorporate 
a variety of correlative science questions to investigate for 
potential biomarkers predictive of bevacizumab beneﬁ  t.
Conclusion
The ECOG 4599 trial demonstrated that the addition of beva-
cizumab to standard chemotherapy resulted in a statistically 
signiﬁ  cant and clinically relevant improvement in overall 
survival. This pivotal trial conﬁ  rmed the extensive preclinical 
data that inhibiting angiogenesis would be an effective treat-
ment and the critical role VEGF has in the process of tumor 
growth and metastases in NSCLC. This led to the FDA to 
approve bevacizumab for treatment for patients with advanced 
NSCLC and non-squamous histology in combination with 
carboplatin and paclitaxel. Bevacizumab is the ﬁ  rst and only 
targeted therapy to extend survival when combined with 
chemotherapy in the ﬁ  rst-line treatment of advanced NSCLC. 
The carefully selected inclusion criteria limited enrollment 
to patients who were at lower risk for bevacizumab-related 
bleeding complications; however, even in this select popula-
tion the bevacizumab containing treatment had a statistically 
signiﬁ  cant higher rate of grade 3–5 hemorrhage than seen with 
standard therapy. Current trials will investigate the safety of 
bevacizumab in patient populations excluded from ECOG 
4599, and the efﬁ  cacy and safety of bevacizumab in early 
and locally advanced stage disease. As with any therapeutic 
advance, additional studies will be required to determine the 
optimal integration into the current treatment paradigms, 
the selection of patients who are most likely to beneﬁ  t, and 
the selection of patients at lowest risk of toxicity.
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